Trimethylammonium

Trimethylammonium

SCHEMBL869520

C=C(C)C(=O)NCCC.CN(C)C.Cl

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA known ✓ P10253 1/20 0.41
MMP1 known ✓ P03956 1/20 0.38
CHRNB4 known ✓ P30926 1/20 0.35
CHRNA3 known ✓ P32297 1/20 0.35
ACHE known ✓ P22303 1/20 0.31
NPC1 O15118 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP9 P14780 1/20 0.38
EPHX1 P07099 2/20 0.36
PAOX Q6QHF9 1/20 0.35
MCL1 Q07820 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
TGFBR1 P36897 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM4E B2RXH2 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trimethylammonium SCHEMBL635942 1.00 NPC1 (0.41) NPC1GAAMAPTRAB9ASMN1; SMN2
Trimethylammonium SCHEMBL28199923 0.98 NPC1 (0.40) NPC1GAAMAPTRAB9ASMN1; SMN2
Trimethylammonium SCHEMBL21743 0.98 NPC1 (0.42) NPC1GAAMAPTRAB9ASMN1; SMN2
Acetic Acid SCHEMBL9389723 0.96 NPC1 (0.39) NPC1GAAMAPTRAB9ASMN1; SMN2
Trimethylammonium SCHEMBL27347511 0.96 NPC1 (0.41) NPC1GAAMAPTRAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL3148805 0.94 MMP1 (0.41) NPC1GAAMAPTRAB9ASMN1; SMN2
N,N-Dimethylethanaminium SCHEMBL7062326 0.92 NPC1 (0.39) NPC1GAAMAPTRAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL28010702 0.91 MMP1 (0.40) NPC1GAAMAPTRAB9ASMN1; SMN2
SCHEMBL149370 0.91
N,N-Dimethylethanaminium SCHEMBL446053 0.90 NPC1 (0.40) NPC1GAAMAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117186857-A Gel breaking temporary plugging liquid and preparation method and application thereof 中国石油天然气股份有限公司 2023-12-08 CN claimed
US-11793198-B2 Disinfectant composition THE PROCTER & GAMBLE COMPANY (US) 2023-10-24 US claimed
CN-114080156-B Disinfectant composition 宝洁公司 2023-05-23 CN claimed
CN-115678440-B OCA optical cement for 3D curved screen and preparation method and application thereof 广州鹿山新材料股份有限公司 2023-03-21 CN claimed
US-20230056285-A1 DISINFECTANT COMPOSITION PROCTER & GAMBLE (US) 2023-02-23 US claimed
CN-115678440-A OCA optical adhesive for 3D curved screen and preparation method and application thereof 广州鹿山新材料股份有限公司 2023-02-03 CN claimed
CN-114736393-A Conductive hydrogel and preparation method and application thereof 浙江清华柔性电子技术研究院 2022-07-12 CN claimed
CN-114080156-A Disinfectant composition 宝洁公司 2022-02-22 CN claimed
CN-114040677-A Disinfectant composition 宝洁公司 2022-02-11 CN claimed
CN-110161243-B Nano artificial antibody inhibitor for real-time imaging of tumor marker in living cell and preparation method thereof 北京化工大学 2021-05-04 CN claimed
WO-2012061305-A1 SURFACE APPLICATION OF POLYMERS TO IMPROVE PAPER STRENGTH HERCULES INCORPORATED (US) 2012-05-10 WO claimed
US-20120111517-A1 Surface Application of Polymers to Improve Paper Strength THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS NOTES COLLATERAL AGENT 2012-05-10 US claimed
US-7807766-B2 Polymers for use in cleaning compositions COGNIS IP MANAGEMENT GMBH (DE) 2010-10-05 US claimed
US-20070179265-A1 POLYMERS FOR USE IN CLEANING COMPOSITIONS COGNIS IP MANAGEMENT GMBH (DE) 2007-08-02 US claimed
EP-1539846-A1 GRAFT COPOLYMERS, THEIR PREPARATION AND USE IN CAPILLARY ELECTROPHORESIS Applera Corporation (US) 2005-06-15 EP claimed
WO-2004011513-A1 GRAFT COPOLYMERS, THEIR PREPARATION AND USE IN CAPILLARY ELECTROPHORESIS APPLERA CORPORATION (US) 2004-02-05 WO claimed
US-6656507-B2 Mixture of polymethacrylate and carboxymethyl cellulose ROEHM GMBH & CO. KG (DE) 2003-12-02 US claimed
US-20010055619-A1 AQUEOUS DISPERSION SUITABLE FOR THE PRODUCTION OF COATINGS AND BINDERS FOR SOLID ORAL DRUGS ROHM GMBH (DE) 2001-12-27 US claimed
US-6049733-A Electrotransport system with ion exchange material competitive ion capture ALZA CORPORATION (US) 2000-04-11 US claimed
US-5180757-A Curable acrylate monomers with photoinitiators for printing inks and protective coatings MLT/MICRO-LITE TECHNOLOGY CORPORATION 1993-01-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11793198-B2 Disinfectant composition ALKBH1, ALKBH5, POLL GAA 2404/4885MMP1 2973/4885CHRNB4 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.